Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States

Abstract

Based on this analysis of real-world use of TNF-inhibitors among patients in nationwide clinical practice settings, the annual TNF-inhibitor cost per treated patient was lowest for etanercept across all indications.